Health In Tech, Inc. (HIT) Key Metrics
HIT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $42.6M
- Enterprise value
- $51.3M
- P/E (TTM)
- —
- Forward P/E
- 8.8
- PEG ratio
- —
- Price / sales
- 1.3
- Price / book
- 3.0
- EV / EBITDA
- 291.3
- Dividend yield
- —
- Beta
- —
HIT key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHIT valuation Price multiples at each fiscal year-end price.
HIT returns How much profit the business earns on the capital it uses.
HIT per-share figures Results divided by the shares outstanding at year-end.
HIT financial health Debt, liquidity and how easily interest is covered.
HIT efficiency & capital use Working capital cycle and where the cash goes.
HIT valuation history
HIT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HIT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HIT price vs earnings per share
HIT key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $91.8M | $287.4M | — | — |
| Enterprise value | $84.3M | $279.7M | — | — |
| P/E ratio | 71.8 | 428.6 | — | — |
| Price / sales | 2.8 | 14.7 | — | — |
| Price / book | 5.4 | 21.8 | — | — |
| Price / free cash flow | — | 225.3 | — | — |
| Price / operating cash flow | 29.3 | 132.0 | — | — |
| EV / sales | 2.5 | 14.4 | — | — |
| EV / EBITDA | 32.7 | 145.3 | — | — |
| EV / free cash flow | — | 219.3 | — | — |
| Earnings yield | 1.4% | 0.2% | — | — |
| Free cash flow yield | −0.1% | 0.4% | — | — |
| Share price at fiscal year-end | $1.59 | $5.36 | — | — |
| Per share | ||||
| Revenue per share | $0.58 | $0.36 | $0.35 | $0.11 |
| Earnings per share | $0.02 | $0.01 | $0.05 | $0.00 |
| Operating cash flow per share | $0.05 | $0.04 | $0.03 | $0.01 |
| Free cash flow per share | −$0.00 | $0.02 | $0.01 | −$0.01 |
| Cash per share | $0.13 | $0.15 | $0.04 | $0.03 |
| Book value per share | $0.30 | $0.25 | $0.11 | $0.02 |
| Tangible book value per share | $0.18 | $0.17 | $0.05 | −$0.03 |
| Capex per share | $0.06 | $0.02 | $0.02 | $0.02 |
| Debt per share | $0.00 | $0.00 | $0.04 | $0.01 |
| Shares outstanding | 57.7M | 53.7M | 54.1M | 54.1M |
| Change in shares outstanding | +7.6% | −0.8% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | 8.4% | 7.0% | 69.3% | 7.6% |
| Return on invested capital (ROIC) | 15.5% | 13.4% | 89.5% | — |
| Return on assets (ROA) | 6.6% | 4.9% | 12.4% | 0.3% |
| Return on tangible assets | 7.7% | 5.7% | 31.2% | 0.3% |
| Free cash flow margin | −0.2% | 6.5% | 2.0% | −7.6% |
| Income quality (OCF / net income) | 2.45 | 3.25 | 0.62 | 9.82 |
| Financial health | ||||
| Total debt | $139,812 | $206,692 | $1.9M | $316,090 |
| Cash & short-term investments | $7.7M | $7.8M | $2.4M | $1.5M |
| Net debt | −$7.5M | −$7.6M | −$501,175 | −$1.2M |
| Debt / equity | 0.01 | 0.02 | 0.31 | 0.30 |
| Debt / assets | 0.01 | 0.01 | 0.17 | 0.01 |
| Net debt / EBITDA | −2.92 | −3.97 | −0.13 | −5.70 |
| Current ratio | 3.13 | 5.06 | 1.43 | 1.06 |
| Quick ratio | 3.13 | 5.06 | 1.43 | 1.06 |
| Interest coverage | — | 2.0 | — | 45.0 |
| Working capital | $11.0M | $8.7M | $2.1M | $1.4M |
| Invested capital | $9.6M | $5.5M | $5.6M | −$121,335 |
| Tangible asset value | $10.6M | $9.2M | $2.5M | −$1.3M |
| Net current asset value | $10.2M | $8.2M | $1.4M | −$1.7M |
| Graham number | $0.38 | $0.26 | $0.34 | $0.03 |
| Graham net-net per share | $0.09 | $0.13 | −$0.00 | −$0.46 |
| Capital allocation | ||||
| Capex / revenue | 9.6% | 4.6% | 6.0% | 21.1% |
| Capex / operating cash flow | 101.8% | 41.4% | 74.8% | 155.8% |
| Capex / depreciation | 3.54 | 1.66 | 3.37 | — |
| Stock-based compensation / revenue | 4.7% | 2.4% | 0.0% | 9.8% |
| R&D / revenue | 4.7% | 14.4% | 10.5% | 13.8% |
| SG&A / revenue | 53.5% | 59.7% | 59.8% | 76.9% |
| Efficiency | ||||
| Days sales outstanding | 39.4 | 56.8 | 46.6 | 61.8 |
| Days payables outstanding | 89.1 | 201.8 | 245.2 | 518.1 |
| Cash conversion cycle (days) | -49.7 | -145.0 | -198.6 | -456.3 |
| Receivables turnover | 9.27 | 6.43 | 7.83 | 5.91 |
| Payables turnover | 4.10 | 1.81 | 1.49 | 0.70 |
| Asset turnover | 1.72 | 1.43 | 0.96 | 0.20 |
| Average receivables | $3.6M | $3.0M | $2.4M | $976,861 |
| Average payables | $3.0M | $2.2M | $1.5M | $474,395 |
| Intangibles / total assets | 28.3% | 25.1% | 31.0% | 9.7% |
Computed from HIT's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HIT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Health In Tech traded at 71.8 times earnings. Health In Tech earned a return on equity of 8.4% and a return on invested capital of 15.5% in fiscal 2025. It ended the year with $0.1 million of debt and $7.7 million in cash and short-term investments, a net cash position of $7.5 million.
See the HIT income statement, the HIT chart for price history, or the HIT stock overview for the latest quote and news.
HIT key metrics FAQ
What is Health In Tech's P/E ratio?
Health In Tech traded at 71.8 times earnings at the end of fiscal 2025.
What is Health In Tech's EV/EBITDA?
Health In Tech's enterprise value was 32.7 times EBITDA at the end of fiscal 2025 (enterprise value $84.3 million, EBITDA $2.6 million); the current EV/EBITDA is 291.3.
What is Health In Tech's return on equity?
Health In Tech's return on equity (ROE) was 8.4% in fiscal 2025: net income of $1.3 million on average shareholders' equity of $15.1 million.
What is Health In Tech's ROIC?
Health In Tech's return on invested capital was 15.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Health In Tech have?
Health In Tech had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Health In Tech's free cash flow yield?
Health In Tech generated -$0.1 million of free cash flow in fiscal 2025, a free cash flow yield of −0.1% on its market value at year-end ($91.8 million).
What is Health In Tech's current ratio?
Health In Tech's current ratio was 3.13 at the end of fiscal 2025: current assets were 3.13 times current liabilities.